Evaluation of IGM-2644 in Adults With Relapsed and/or Refractory Multiple Myeloma
Summary
Third Opinion Trial Synopsis:
This study is testing a new medicine called IGM-2644 on people with a type of cancer called multiple myeloma. The medicine will be given to people who have tried other treatments that didn't work, or had bad side effects. The study will look at how safe the medicine is and how well it works. It will take about 60 months to finish the study.
This study is testing a new medicine called IGM-2644 on people with a type of cancer called multiple myeloma. The medicine will be given to people who have tried other treatments that didn't work, or had bad side effects. The study will look at how safe the medicine is and how well it works. It will take about 60 months to finish the study.
*Third Opinion AI Generated Synopsis
Trial Summary
This is a first in human, phase 1, multicenter, open-label study to determine the safety and tolerability of IGM-2644 as a single agent in participants with relapsed and/or refractory MM, for whom standard therapy does not exist, has proven to be ineffective or intolerable, or is considered inappropriate. Dose escalation and dose expansion cohorts will be enrolled to evaluate safety, preliminary efficacy, and further define a RP2D. The total length of the study, from screening of the first participant to the end of the study, is expected to be approximately 60 months.
This is a first in human, phase 1, multicenter, open-label study to determine the safety and tolerability of IGM-2644 as a single agent in participants with relapsed and/or refractory MM, for whom standard therapy does not exist, has proven to be ineffective or intolerable, or is considered inappropriate. Dose escalation and dose expansion cohorts will be enrolled to evaluate safety, preliminary efficacy, and further define a RP2D. The total length of the study, from screening of the first participant to the end of the study, is expected to be approximately 60 months.
Locations & Contact
Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts: